Valerion Therapeutics is an emerging science-driven company focused on the development of bio-therapeutics for orphan genetic diseases. Valerion utilizes a proprietary cell-penetrating antibody to target the cytoplasm of affected tissues - a cell compartment previously out of reach for protein-based therapies. Our versatile platform can be conjugated to proteins, small molecules & oligonucleotides providing a novel pathway to treat previously intractable diseases.